{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-074003","form_type":"8-K","ticker":"TRAW","cik":"0001130598","company_name":"Traws Pharma, Inc.","filed_at":"2024-06-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.393378+00:00","generated_at":"2026-06-01T02:42:00.849134+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Traws Pharma President & CSO Oncology resigns; Board disputes severance claim","bullets":["Steven M. Fruchtman resigned as President and Chief Scientific Officer, Oncology, effective June 17, 2024.","Fruchtman's attorney claims resignation is for 'good reason' under employment agreement, expecting severance related to change in control.","Board accepted resignation immediately but disagrees with characterization; believes no severance payments are due.","Victor Moyo continues as Chief Medical Officer, Oncology."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-074003","json":"https://secwatch.observer/filing/0001104659-24-074003.json","markdown":"https://secwatch.observer/filing/0001104659-24-074003.md","text":"https://secwatch.observer/filing/0001104659-24-074003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130598/000110465924074003/0001104659-24-074003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130598/000110465924074003/tm2417729d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T02:42:00.849134+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9b260a6dc7","claim":"Steven M. Fruchtman resigned as President and Chief Scientific Officer, Oncology at Traws Pharma, Inc..","evidence_excerpt":"On June 17, 2024, Steven M. Fruchtman informed the board of directors (the “Board”) of Traws Pharma, Inc. (the “Company”) of his intent to resign from his positions of President and Chief Scientific Officer, Oncology.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465924074003/0001104659-24-074003-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Chief Scientific Officer, Oncology"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}